Clinical Trial Update: Ambrisentan for Treatment of Portopulmonary Hypertension [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 trial of Ambrisentan for portopulmonary hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Portopulmonary Hypertension

Drugs mentioned

• Ambrisentan (Ambrisentan)

Snippet

Sponsor: Medical University of Graz | Conditions: Portopulmonary Hypertension | Phase 1, Phase 2 | Status: WITHDRAWN